Nothing Special   »   [go: up one dir, main page]

HK1224370A1 - 用於肝癌的無創診斷的特異性生物標誌物組 - Google Patents

用於肝癌的無創診斷的特異性生物標誌物組

Info

Publication number
HK1224370A1
HK1224370A1 HK16106781.2A HK16106781A HK1224370A1 HK 1224370 A1 HK1224370 A1 HK 1224370A1 HK 16106781 A HK16106781 A HK 16106781A HK 1224370 A1 HK1224370 A1 HK 1224370A1
Authority
HK
Hong Kong
Prior art keywords
liver cancer
specific biomarker
invasive diagnosis
biomarker set
invasive
Prior art date
Application number
HK16106781.2A
Other languages
English (en)
Inventor
文詠賢
衛鳳文
黃炳鏐
衛智賢
Original Assignee
Dragon Victory Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Application filed by Dragon Victory Dev Ltd filed Critical Dragon Victory Dev Ltd
Publication of HK1224370A1 publication Critical patent/HK1224370A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
HK16106781.2A 2014-07-02 2016-06-13 用於肝癌的無創診斷的特異性生物標誌物組 HK1224370A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer

Publications (1)

Publication Number Publication Date
HK1224370A1 true HK1224370A1 (zh) 2017-08-18

Family

ID=55019816

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16106781.2A HK1224370A1 (zh) 2014-07-02 2016-06-13 用於肝癌的無創診斷的特異性生物標誌物組
HK18107745.3A HK1248803A1 (zh) 2014-07-02 2016-06-13 用於肝癌的無創診斷的特異性生物標誌物組

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18107745.3A HK1248803A1 (zh) 2014-07-02 2016-06-13 用於肝癌的無創診斷的特異性生物標誌物組

Country Status (13)

Country Link
EP (1) EP3164711A4 (zh)
JP (2) JP2017520763A (zh)
KR (1) KR102086788B1 (zh)
CN (2) CN107478842B (zh)
AU (2) AU2014399919B2 (zh)
CA (1) CA2939912C (zh)
HK (2) HK1224370A1 (zh)
MY (2) MY179845A (zh)
NZ (1) NZ722492A (zh)
SG (1) SG11201606106SA (zh)
TW (1) TWI700493B (zh)
UY (1) UY36200A (zh)
WO (1) WO2016003479A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (zh) * 2016-09-02 2020-03-17 四川大学 一种诊断肝癌的标记物组合及其应用
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
KR102175265B1 (ko) 2019-03-13 2020-11-06 충남대학교산학협력단 Txndc7을 포함하는 간세포암종 진단 또는 예후 예측용 바이오마커 조성물
CN110646615B (zh) * 2019-08-27 2021-07-13 南方医科大学 肝纤维化的生物学标志物、治疗靶点及其用途
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
EP4179111B1 (en) 2020-07-10 2024-04-03 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN113502328A (zh) * 2021-05-27 2021-10-15 深圳市人民医院 检测样本中标志物表达水平的试剂在制备用于检测或诊断乳腺癌的试剂盒中的应用
CN113777295B (zh) * 2021-09-15 2024-03-19 江南大学 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN114113611B (zh) * 2021-12-13 2023-07-14 郑州大学 一种用于肝癌诊断的生物标志物及检测试剂盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6449562B1 (en) * 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
US20040241653A1 (en) * 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP3960614B2 (ja) * 2003-08-31 2007-08-15 株式会社イムノディア 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
JP2008502891A (ja) * 2004-06-18 2008-01-31 エフ．ホフマン−ラ　ロシュ　アーゲー 乳癌のマーカーとしてのタンパク質ｐｄｘ１の使用
JP5211315B2 (ja) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
CN101796415B (zh) * 2007-08-10 2014-03-12 学校法人兵库医科大学 新型肝癌标志物
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
JP5493130B2 (ja) * 2010-08-25 2014-05-14 国立大学法人山口大学 自己抗体の検出方法
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
US20130130355A1 (en) 2011-09-28 2013-05-23 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Also Published As

Publication number Publication date
EP3164711A4 (en) 2018-05-23
HK1248803A1 (zh) 2018-10-19
MY179845A (en) 2020-11-18
EP3164711A1 (en) 2017-05-10
NZ722492A (en) 2019-09-27
AU2014399919B2 (en) 2019-10-24
TW201602579A (zh) 2016-01-16
JP2017520763A (ja) 2017-07-27
CN107478842A (zh) 2017-12-15
TWI700493B (zh) 2020-08-01
UY36200A (es) 2016-01-29
AU2017232129A1 (en) 2017-10-12
CA2939912C (en) 2019-04-16
MY195045A (en) 2023-01-04
KR20170021234A (ko) 2017-02-27
CA2939912A1 (en) 2016-01-07
CN107478842B (zh) 2020-10-16
WO2016003479A1 (en) 2016-01-07
AU2014399919A1 (en) 2016-08-11
JP2020160082A (ja) 2020-10-01
SG11201606106SA (en) 2016-08-30
AU2017232129B2 (en) 2018-10-25
CN105319362A (zh) 2016-02-10
CN105319362B (zh) 2018-07-13
KR102086788B1 (ko) 2020-03-09

Similar Documents

Publication Publication Date Title
IL272572B (en) Antibody preparations to treat cancer
SG10202011339RA (en) Microrna biomarker for the diagnosis of gastric cancer
ZA201701753B (en) Biomarkers for assessing breast cancer
HK1248803A1 (zh) 用於肝癌的無創診斷的特異性生物標誌物組
IL285077A (en) Compounds for the treatment of cancer
SI3122358T1 (sl) Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
GB201420859D0 (en) Tumour analysis
IL251376A0 (en) Methods for assessing the risk of developing breast cancer
EP3227686A4 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
HK1253082A1 (zh) 診斷乳腺癌的方法
SG11201701076TA (en) Diagnosis of cancer
EP3204008A4 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment
SG10201913528PA (en) Methods of diagnosing cancer
PL3152576T3 (pl) Zastosowanie tm9sf4 jako biomarkera egzosomów powiązanych z nowotworem
EP3189332A4 (en) Biomarkers for detection of breast cancer
GB201407837D0 (en) Methods of cancer therapy
IL248126A0 (en) Combinations of cancer treatments
GB201410118D0 (en) Early diagnosis of leptospire
GB201414362D0 (en) Biomarkers for early diagnosis of ovarian cancer
ZA201704589B (en) Compounds for the treatment of cancer
GB201405286D0 (en) Cancer diagnostic
AU2014903898A0 (en) Methods for assessing the risk of developing breast cancer
GB201400387D0 (en) Diagnostic for gastric cancer
GB201411489D0 (en) Kit for diagnosis of foetal distress
AU2014901825A0 (en) Biomarker of Disease